Related Experiment Video

Updated: Dec 13, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K

COVID-19 infection and thrombosis

Swati Srivastava1, Iti Garg1, Anju Bansal1

  • 1Genomics Group, Defence Institute of Physiology and Allied Science, Lucknow Road, Timarpur, Delhi 110054, India.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|July 27, 2020
PubMed

Insights

COVID-19 infection can cause dangerous blood clots due to inflammation and coagulation issues. Monitoring clotting factors and using anticoagulants can help prevent and treat thrombosis in patients.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Critical Care Medicine

Background:

  • COVID-19, caused by SARS-CoV-2, is linked to abnormal blood clot formation.
  • Viral infection triggers inflammation, endothelial damage, and coagulation cascade dysfunction.
  • This can lead to disseminated intravascular coagulation (DIC) and coagulopathy, increasing thrombosis risk.

Discussion:

  • This report synthesizes research on COVID-19-associated thrombosis and therapeutic strategies.
  • It reviews studies on coagulopathy, elevated D-dimer, fibrinogen, and altered coagulation parameters (PT, PTT, platelets).
  • Clinical implications for managing COVID-19 patients with clotting complications are discussed.

Key Insights:

  • COVID-19 patients exhibit elevated D-dimer, FDP, and abnormal coagulation parameters.
  • Thrombosis and coagulopathy are significant complications, potentially leading to mortality.
  • Early screening of coagulation parameters is crucial for risk assessment.

Outlook:

  • Clinicians should exercise caution when treating COVID-19 patients.
  • Regular monitoring of coagulation parameters is recommended throughout treatment.
  • Anticoagulant therapy serves as a thromboprophylaxis measure, requiring individualized dosing and duration.
Abstract

Keywords:
COVID-19CoagulopathyHypercoagulabilityLMWHThrombosis

More Related Videos

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

897
Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis03:57

Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis

Published on: March 17, 2023

2.2K

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
168
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
184
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
186
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K